Cargando…
The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment
Clinical trials and real-world data have proven that hepatitis C virus (HCV) in most infected patients can be eradicated by direct-acting antivirals (DAAs). However, the proper retreatment regimen for hemodialysis patients with HCV infection who have previously failed to respond to DAAs has not been...
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Japanese Society of Internal Medicine
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478991/ https://www.ncbi.nlm.nih.gov/pubmed/30568153 http://dx.doi.org/10.2169/internalmedicine.2077-18 |
| _version_ | 1783413257294315520 |
|---|---|
| author | Suda, Goki Nakai, Masato Sho, Takuya Kimura, Megumi Shimazaki, Tomoe Maehara, Osamu Shigesawa, Taku Suzuki, Kazuharu Nakamura, Akihisa Ohara, Masatsugu Umemura, Machiko Kawagishi, Naoki Baba, Masaru Natsuizaka, Mitsuteru Morikawa, Kenichi Ogawa, Koji Sakamoto, Naoya |
| author_facet | Suda, Goki Nakai, Masato Sho, Takuya Kimura, Megumi Shimazaki, Tomoe Maehara, Osamu Shigesawa, Taku Suzuki, Kazuharu Nakamura, Akihisa Ohara, Masatsugu Umemura, Machiko Kawagishi, Naoki Baba, Masaru Natsuizaka, Mitsuteru Morikawa, Kenichi Ogawa, Koji Sakamoto, Naoya |
| author_sort | Suda, Goki |
| collection | PubMed |
| description | Clinical trials and real-world data have proven that hepatitis C virus (HCV) in most infected patients can be eradicated by direct-acting antivirals (DAAs). However, the proper retreatment regimen for hemodialysis patients with HCV infection who have previously failed to respond to DAAs has not been clarified. We herein report, for the first time, the successful retreatment with glecaprevir and pibrentasvir, of three hemodialysis patients with genotype 1 or 2 HCV infection, who had previously failed to respond to combination therapy with an HCV-NA5A inhibitor (daclatasvir) and an HCV protease inhibitor (asunaprevir). |
| format | Online Article Text |
| id | pubmed-6478991 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | The Japanese Society of Internal Medicine |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-64789912019-04-24 The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment Suda, Goki Nakai, Masato Sho, Takuya Kimura, Megumi Shimazaki, Tomoe Maehara, Osamu Shigesawa, Taku Suzuki, Kazuharu Nakamura, Akihisa Ohara, Masatsugu Umemura, Machiko Kawagishi, Naoki Baba, Masaru Natsuizaka, Mitsuteru Morikawa, Kenichi Ogawa, Koji Sakamoto, Naoya Intern Med Case Report Clinical trials and real-world data have proven that hepatitis C virus (HCV) in most infected patients can be eradicated by direct-acting antivirals (DAAs). However, the proper retreatment regimen for hemodialysis patients with HCV infection who have previously failed to respond to DAAs has not been clarified. We herein report, for the first time, the successful retreatment with glecaprevir and pibrentasvir, of three hemodialysis patients with genotype 1 or 2 HCV infection, who had previously failed to respond to combination therapy with an HCV-NA5A inhibitor (daclatasvir) and an HCV protease inhibitor (asunaprevir). The Japanese Society of Internal Medicine 2018-12-18 2019-04-01 /pmc/articles/PMC6478991/ /pubmed/30568153 http://dx.doi.org/10.2169/internalmedicine.2077-18 Text en Copyright © 2019 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Case Report Suda, Goki Nakai, Masato Sho, Takuya Kimura, Megumi Shimazaki, Tomoe Maehara, Osamu Shigesawa, Taku Suzuki, Kazuharu Nakamura, Akihisa Ohara, Masatsugu Umemura, Machiko Kawagishi, Naoki Baba, Masaru Natsuizaka, Mitsuteru Morikawa, Kenichi Ogawa, Koji Sakamoto, Naoya The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment |
| title | The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment |
| title_full | The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment |
| title_fullStr | The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment |
| title_full_unstemmed | The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment |
| title_short | The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment |
| title_sort | successful retreatment with glecaprevir and pibrentasvir of genotype 1 or 2 hcv-infected hemodialysis patients who failed to respond to ns5a and protease inhibitor treatment |
| topic | Case Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478991/ https://www.ncbi.nlm.nih.gov/pubmed/30568153 http://dx.doi.org/10.2169/internalmedicine.2077-18 |
| work_keys_str_mv | AT sudagoki thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT nakaimasato thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT shotakuya thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT kimuramegumi thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT shimazakitomoe thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT maeharaosamu thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT shigesawataku thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT suzukikazuharu thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT nakamuraakihisa thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT oharamasatsugu thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT umemuramachiko thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT kawagishinaoki thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT babamasaru thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT natsuizakamitsuteru thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT morikawakenichi thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT ogawakoji thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT sakamotonaoya thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT thesuccessfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT sudagoki successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT nakaimasato successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT shotakuya successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT kimuramegumi successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT shimazakitomoe successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT maeharaosamu successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT shigesawataku successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT suzukikazuharu successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT nakamuraakihisa successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT oharamasatsugu successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT umemuramachiko successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT kawagishinaoki successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT babamasaru successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT natsuizakamitsuteru successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT morikawakenichi successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT ogawakoji successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT sakamotonaoya successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment AT successfulretreatmentwithglecaprevirandpibrentasvirofgenotype1or2hcvinfectedhemodialysispatientswhofailedtorespondtons5aandproteaseinhibitortreatment |